Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 17:9:11.
doi: 10.1186/1472-6815-9-11.

Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients

Wafa Allam  1 , Nabil Ismaili, Sanaa Elmajjaoui, Bel K Elgueddari, Mohammed Ismaili, Hassan Errihani
Affiliations

Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients

Wafa Allam et al. BMC Ear Nose Throat Disord. .

Abstract

Background: Nasopharyngeal non-Hodgkin lymphomas (NNHL) are extremely rare. In this study, we will report the progress achieved in the management of this disease in our institute.

Methods: We retrospectively reviewed the records of 26 patients having primary NNHL who were managed between January 1997 and December 2008, to evaluate and compare their clinical characteristics and treatment outcome. Clinical variables, including age, sex, stage, and treatment modality, were assessed. Disease free survival and overall survival were measured. Survival curves were constructed using the KaplanMeier method. The log-rank test was used to compare them.

Results: Median age of our patients was 52.7 years. Nasal obstruction, nasal discharge and epistaxis were the frequent symptoms in NNHL patients. Histology of NNHL were mainly large B-cell and follicular lymphoma. Four patients (15.4%) were at stage I, 15 (57.6%) at stage II, and 7 (27%) were at stage III/IV. The patients were treated with chemotherapy alone (27%) or chemotherapy plus radiotherapy (73%). At early stage (stage I/II), the patients were managed with chemo-radiotherapy. When the whole treatment was completed, 18 patients (69.2%) achieved complete response and remained disease free. After 25.9 months median follow-up, overall survival at 1 year was 87% and disease free survival at 1 year was 71%. The difference in term of overall and disease free survival between stage I, II, III and IV was significant (Log rank test: p = 0.02 for overall survival and p = 0.01 for disease free survival).

Conclusion: From our study, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are particular and more studies have to be directed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates for overall survival for the entire patients.
Figure 2
Figure 2
Kaplan-Meier estimates for disease free survival for the entire patients.
Figure 3
Figure 3
Kaplan -Meier curves for the Overall survival by stage (Log-rank test: p = 0.02). No difference between the curves for stage I and II: (curves are superimposed), but a significant difference with advanced stages III and IV.
Figure 4
Figure 4
Kaplan-Meier curves for disease free survival according to the NNHL stage. (Significant difference between the stages: Log-rank test: p = 0.01)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DePeña CA, Van Tassel P, Lee YY. Imaging Hodgkin and Non-Hodgkin Lymphoma in the Head and Neck. Radiologic Clinics of North America. 1990;28(4):723–743. - PubMed
    1. Essadi I, Ismaili N, Tazi E, Elmajjaoui S, Saidi A, Ichou M. Primary lymphoma of the head and neck: two case reports and review of the literature. Cases J. 2008;1:426. doi: 10.1186/1757-1626-1-426. - DOI - PMC - PubMed
    1. Jordan RC, Speight PM. Extranodal non hodgkin's lymphomas of the oral cavity. Curr Top Pathol. 1996;90:125–146. - PubMed
    1. Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin's Disease staging Classification. Cancer Res. 1971;31:1860–1. - PubMed
    1. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;10;25(5):579–86. doi: 10.1200/JCO.2006.09.2403. - DOI - PubMed

LinkOut - more resources